SynBioBeta Speaker
Amy Jenkins
AstraZeneca
Sr Dir, Strat & Ops
Dr. Amy Jenkins is currently the Senior Director of Strategy and Operations within the Vaccines and Immune Therapies Unit at AstraZeneca. Prior to joining AstraZeneca, Dr. Jenkins was the Acting Deputy Director of the Advanced Research Projects Agency for Health (ARPA-H) assisting in the management of the agency from a strategic planning and scientific perspective. She served as the inaugural director of the Health Science Futures Office within ARPA-H where she managed a diverse office focused on revolutionary technology innovations in osteoarthritis, cancer, cell and gene therapy, vaccinology, manufacturing, and neuroscience.
She also served as a program manager in the Biological Technologies Office at DARPA. Her portfolio included programs aimed at the development of platforms for combatting infectious disease threats using nucleic acid vectored monoclonal antibodies and novel synthetic biology tools. She had a particular focus within her portfolio on novel manufacturing methods to enable rapid response. She has served as a Project Coordination Team lead for Operation Warp Speed, driving the development of monoclonal antibodies for the treatment and prevention of covid-19 disease.
She received her Doctor of Philosophy degree in Chemistry and Chemical Biology from Cornell University and her Bachelor of Science in Chemistry and Biomolecular Science from Clarkson University.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Amy
This Year
•
-
Business of Biology
Bio-Ready America: Advancing Bioliteracy to Power the U.S. Bioeconomy
As the U.S. accelerates into the age of biotechnology, the future of our national competitiveness, economic growth, and security depend on a workforce and citizenry fluent in biotechnology. This panel brings together leaders to explore how bioliteracy and a biotech-ready workforce can become strategic assets to power the U.S. bioeconomy.
Purchase Pass
Featuring
Drew Endy
Stanford University
Hoover Inst Fellow
Synthetic biology pioneer, co-founded iGEM and BioBricks.
Amy Jenkins
AstraZeneca
Sr Dir, Strat & Ops
Pandemic-response biotech leader; built rapid antibody platforms.
Stuart Sevier
IMI
President
Physicist turned science-media trust builder amplifying research stories.
•
-
Business of Biology
Bio-Ready America: Advancing Bioliteracy to Power the U.S. Bioeconomy
As the U.S. accelerates into the age of biotechnology, the future of our national competitiveness, economic growth, and security depend on a workforce and citizenry fluent in biotechnology. This panel brings together leaders to explore how bioliteracy and a biotech-ready workforce can become strategic assets to power the U.S. bioeconomy.
Purchase Pass
Featuring
Drew Endy
Stanford University
Hoover Inst Fellow
Synthetic biology pioneer, co-founded iGEM and BioBricks.
Amy Jenkins
AstraZeneca
Sr Dir, Strat & Ops
Pandemic-response biotech leader; built rapid antibody platforms.
Stuart Sevier
IMI
President
Physicist turned science-media trust builder amplifying research stories.
Session lineup still growing
Purchase Pass
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Purchase Pass
Featuring
Speaker Coming Soon
